MRI contrast agents are required in the clinic to detect some pathologies, such as cancers. Nevertheless, at the moment, only small extracellular and non-specific gadolinium complexes are available for clinicians. Moreover, safety issues have recently emerged concerning the use of gadolinium complexes; hence, alternatives are urgently needed. Manganese-based MRI contrast agents could be one of these alternatives and increasing numbers of studies are available in the literature. This review aims at synthesizing all the research, from small Mn complexes to nanoparticular agents, including theranostic agents, to highlight all the efforts already made by the scientific community to obtain highly efficient agents but also evidence of the weaknesses of the developed systems.

Knowledge of the longitudinal and transverse relaxation times (T₁ and T₂) of water protons in an aqueous solution of an MRI contrast agent is essential for its characterization. These parameters can be measured at low field on low resolution spectrometers or at high field on high resolution spectrometers. The reliability and the accuracy of T₁ and T₂ measurements rely on several experimental settings and on the equation used to fit the data. Examples of the importance of careful adjustment of the most important parameters are illustrated through several measurements performed on a low‐resolution, low‐magnetic field instrument. In addition, some specificities of T₁ and T₂ measurements on high‐resolution, high‐magnetic field spectrometers are pointed out. Copyright © 2009 John Wiley & Sons, Ltd.

The growing concern over the toxicity of Gd-based contrast agents used in magnetic resonance imaging (MRI) motivates the search for less toxic and more effective alternatives. Among these alternatives, iron–iron oxide (Fe@FeOx) core-shell architectures have been long recognized as promising MRI contrast agents while limited information on their engineering is available. Here we report the synthesis of 10 nm large Fe@FeOx nanoparticles, their coating with a 11 nm thick layer of dense silica and functionalization by 5 kDa PEG chains to improve their biocompatibility. The nanomaterials obtained have been characterized by a set of complementary techniques such as infra-red and nuclear magnetic resonance spectroscopies, transmission electron microscopy, dynamic light scattering and zetametry, and magnetometry. They display hydrodynamic diameters in the 100 nm range, zetapotential values around −30 mV, and magnetization values higher than the reference contrast agent RESOVIST^®. They display no cytotoxicity against 1BR3G and HCT116 cell lines and no hemolytic activity against human red blood cells. Their nuclear magnetic relaxation dispersion (NMRD) profiles are typical for nanomaterials of this size and magnetization. They display high r₂ relaxivity values and low r₁ leading to enhanced r₂/r₁ ratios in comparison with RESOVIST^®. All these data make them promising contrast agents to detect early stage tumors.